Flortaucipir F18

(Tauvid®)

Tauvid®

Drug updated on 7/4/2024

Dosage FormInjection (intravenous; 300 MBq/mL to 1,900 MBq/mL [8.1 mCi/mL to 51 mCi/mL] of flortaucipir F 18 injection in a multiple-dose vial)
Drug ClassRadioactive diagnostic agents
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD).

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated, with no liability accepted for reliance on it. Learn more.

  • Flortaucipir F18 (Tauvid) is utilized for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease.
  • The study on Tauvid was derived from a Randomized Controlled Trial.
  • Two prospective, open-label, longitudinal studies involved 364 participants diagnosed with clinical impairment. These participants underwent flortaucipir PET scans and were followed longitudinally for approximately 18 months.
  • Data showed a significant association between an advanced AD pattern in flortaucipir PET scans and near-term clinical deterioration. Patients with an advanced AD pattern had a higher risk of clinically meaningful deterioration compared to those with non-advanced patterns.
  • Although there was no direct comparison made between Tauvid and other diagnostic tools such as amyloid-beta PET imaging or cerebrospinal fluid biomarkers, it suggests that targeting tau NFTs could offer a complementary or superior approach to amyloid-centric diagnostics due to its role in Alzheimer's progression.
  • The study involved diverse groups including female participants, making up almost half of the population studied, indicating general applicability across genders; however, no specific subgroup considerations were mentioned.